May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
A Biomarker for Retinal Degeneration: Vitreous Body Neurofilaments
Author Affiliations & Notes
  • Z.F. Zagorski
    Ophthalmology, Medical, Lublin, Poland
  • R. Rejdak
    Ophthalmology, Medical, Lublin, Poland
  • A. Junemann
    Ophthalmology, University Erlangen–Nurnberg, Erlangen, Germany
  • K. Rejdak
    Neurology, Medical University, Lublin, Poland
  • T. Zarnowski
    Ophthalmology, Medical, Lublin, Poland
  • A. Mankowska
    Ophthalmology, Medical, Lublin, Poland
  • E. Zrenner
    Pathophysiology of Vision and Neuro–ophthalmology, University Eye Hospital Tuebingen, Tuebingen, Germany
  • F. Kruse
    Ophthalmology, Medical, Lublin, Poland
  • A. Petzold
    Neuroimmunology, Institute of Neurology, Queen Square, London, United Kingdom
  • Footnotes
    Commercial Relationships  Z.F. Zagorski, None; R. Rejdak, None; A. Junemann, None; K. Rejdak, None; T. Zarnowski, None; A. Mankowska, None; E. Zrenner, None; F. Kruse, None; A. Petzold, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5518. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Z.F. Zagorski, R. Rejdak, A. Junemann, K. Rejdak, T. Zarnowski, A. Mankowska, E. Zrenner, F. Kruse, A. Petzold; A Biomarker for Retinal Degeneration: Vitreous Body Neurofilaments . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5518.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Biomarkers are an attractive tool for quantifying neurodegeneration. Neurofilaments can be used to specifically measure neuro–axonal loss because they are generally not expressed in other cell–types. The main aim of this study was to investigate whether the phosphorylated form of the neurofilament heavy chain (NfHSMI35), an important biomarker for axonal degeneration, could be measured from a fluid compartment of the eye.

Methods: : Aqueous humour samples were collected from glaucoma patients who underwent routine trabeculectomy for primary open–angle glaucoma (POAG) or pseudoexfoliation open–angle glaucoma (PEXG). Vitreous humour samples were collected from 14 patients who underwent vitrectomy for retinal detachment (RD) and macular hole (MH) surgery. The control group consisted of patients in whom we did not expect to find any axonal pathology. Two of the control patients suffered from epiretinal gliosis and one underwent vitrectomy during cataract surgery due to a nanophthalmic eye. A previously–described ELISA technique was used to quantify NfH levels.

Results: : Vitreous body homogenate NfHSMI35 levels were detectable in all samples of vitreous body homogenate. There was no correlation between the NfHSMI35 levels and the patients’ age (Spearman’s R=–0.29, p=0.31). The highest value observed in the control group was 0.47 ng/mL NfHSMI35 . Comparable NfHSMI35 levels were observed in patients with MH (0.03 to 0.34 ng/mL). For patients with RD a bimodal distribution was observed with one group having NfHSMI35 levels of 0.06 to 0.23 ng/mL and the other one achieving concentrations of 0.83 to 1.49 ng/mL. Neurofilament levels could not be detected in any of the anterior chamber fluid samples.

Conclusions: : This study is the first to show that NfHSMI35 can be quantified from the vitreous body, but not from the anterior chamber fluid in humans. We hypothesize that high vitreous body NfHSMI35 levels in some RD patients suggests considerable axonal loss

Keywords: vitreous • retina: neurochemistry • degenerations/dystrophies 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.